Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Flolan® Clear all

Conditions: Liver Transplant
Interventions: treprostinil sodium, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension, Pulmonary
Interventions: current marketed FLOLAN (epoprostenol sodium), new thermo stable formulation of epoprostenol sodium; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Miami Beach, Florida • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Pulmonary Arterial Hypertension
Interventions: treprostinil, Crono Five ambulatory pump; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: San Francisco, California • New York, New York • Oklahoma City, Oklahoma

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 8
States / cities: Los Angeles, California • Torrance, California • Chicago, Illinois + 5 more

Conditions: Ischemia Reperfusion Injury, Delayed Graft Function
Interventions: Treprostinil; Drug
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Hypertension, Pulmonary
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pulmonary Arterial Hypertension
Interventions: Oral treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 41
States / cities: Fresno, California • Los Angeles, California • San Juan Capistrano, California + 37 more

Conditions: Hypertension, Pulmonary
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 2
States / cities: La Jolla, California • San Diego, California

Conditions: Pulmonary Hypertension
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pulmonary Arterial Hypertension
Interventions: ACT-385781A (Actelion Epoprostenol), Flolan®; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: La Jolla, California • Aurora, Colorado • Durham, North Carolina + 4 more

Conditions: Pulmonary Arterial Hypertension
Interventions: inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: Not listed
Enrollment: 1,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 88
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more

Search by objective public record fields.

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)

Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH

A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension

Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies